JUL. 6. 2004 2:56PM

## JCWSCS 07 JUL 2004

NO. 4986 P. 1

FAX TO THE UNITED	TRANSMITTAL STATES PATENT OFFICE			
Applicants Docket Number: DEAV2003/0002 US NP Applicants: KLINGLER, et al.	CERTIFICATE OF TRANSMISSION  I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at 703.746-9195, on Date of Deposit			
Serial No. 10/751,545	Signature Phyllis Renée Mc Hinnis			
Filing Date: January 5, 2004	Total Number of Pages Sent: 10 Attorney: Raymond S. PARKER, III			
Title of Invention: SELECTIVE MMP-13 INHIBITORS	Group Art Unit: 1614 Examiner:			
TO: Mail Stop Office of Initial Patent Examina Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450	tion's Filing Receipt Corrections			
	cuments for the above Application by return telefax to charge our deposit account (18-1982) in the name of			

Fee Transmittal

Sheet - 5 pages

Receipt

Petition under 37 CFR \_\_\_\_\_

Other Copy of Filing Receipt

Other Request For Corrected Filing

Other Supplemental Application Data

 $\boxtimes$ 

 $\boxtimes$ 

M

Aventis Pharmaccuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Amendment, 37 CFR \_\_\_\_\_

Extension of Time Petition

Maintenance Fee Transmittal

Charge deposit account, in duplicate

Issue Fee Transmittal & Advance Order

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

KLINGLER, et al.

Examiner:

Art Unit:

1614

Application No.: 10/751,545

Filed: January 5, 2004

Title: SELECTIVE MMP-13 INHUBITORS

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patients, P. O. Box 1450, Alexandria, VA 22313-1450, at (703) 746-9195, on

#### REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop Office of Initial Patent Examination's Filing Receipt Corrections Commissioner of Patents P. O. Box 1450 Alexandria, VA 22313-1450

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that the First named inventor's name is misspelled. It should appear as follows: Otmar KLINGLER.

There is also an error in the order of inventors. Please list the inventors in the following order:

> Otmar KLINGLER Reinhard KIRSCH Joerg HABERMANN Klaus-Ulrich WEITHMANN Christian ENGEL Bernard PIRARD

Also, a supplemental application data sheet is enclosed.

The Commissioner is hereby authorized to charge any fees which are required by this paper to Deposit Account 18-1982.

Respectfully submitted,

dy 6,2004

Raymond'S. Parker, III, Ph.D., Reg. No. 34,893

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-5674
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0002 US NP



United States Patent and Trail

APPL NO. 10/751.545

FILING OR 371 (c) DATE 01/05/2004

ARY UNIT 1614

FIL FEE REC'D 770

ATTY.DOCKET NO

IND CLMS

DEAV20030002USNP

CONFIRMATION NO. 2394

05487 ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC. **ROUTE 202-206** 

MAIL CODE: D303A

BRIDGEWATER, NJ 08807

\*OC000000012325347\*

**FILING RECEIPT** 

Date Mailed: 04/12/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Otmar Klinger, Rodgau, GERMANY; Reinhard Kirsch, Braunschweig, GERMANY; Joerg Habermann, Roma, ITALY; Christian Engel, Frankfurt, GERMANY; Bemard Pirard, Darmstadt, GERMANY; Klaus-Ulrich Weithmann, Hofheim, GERMANY;

### Assignment For Published Patent Application

AVENTIS PHARMA DEUTSCHLAND GMBH, Frankfurt am Main, GERMANY;

#### Domestic Priority data as claimed by applicant

This appln claims benefit of 60/472,765 05/22/2003

#### Foreign Applications

GERMANY 10300017.8 01/03/2003

If Required, Foreign Filing License Granted: 04/09/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Selective MMP-13 inhibitors

**Preliminary Class** 

514

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).